MedTrace Logo

Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

NCT03176628 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-06-27

No results posted yet for this study

Summary

This study will determine the pharmacokinetics, pharmacodynamics and safety of escalating doses of Basis following twice daily oral administration in patients with acute kidney injury (AKI). Basis is a commercially available nutritional supplement consisting of nicotinamide riboside (NR) and pterostilbene that acts to increase sirtuin activity.

Conditions

Interventions

DIETARY_SUPPLEMENT

Basis

NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries

DIETARY_SUPPLEMENT

Placebo

Placebo capsule(s)

Sponsors & Collaborators

  • Elysium Health

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Eugene Rhee, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2018-09-11
Completion
2018-09-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03176628 on ClinicalTrials.gov